Published in Primary Care

Pilocarpine Tolerability: Does Concentration Matter

Mark Schaeffer, OD, FAAO

Jacob Lang, OD, FAAO

This is editorially independent content supported by advertising from Orasis Pharmaceuticals

Apr 27, 2026

4 min read

Join Drs. Schaeffer and Lang as they discuss the significance of pilocarpine tolerability in presbyopia treatment and download the cheat sheet comparing drops.

Pilocarpine Tolerability: Does Concentration Matter- Mark Schaeffer, OD, FAAO and Jacob Lang, OD, FAAO from Eyes On Eyecare Vimeo on Vimeo

On the first episode of Presbyopia Playbook Mark Schaeffer, OD, FAAO clinical excellence captain at MyEyeDr in Birmingham, AL, and founding member and Vice President of the Intrepid Eye Society and Jacob Lang, OD, FAAO, Medical Director of the Dry Eye Service and Ocular Disease Residency Programs at Associated Eye Care in Hudson, WI, and Stillwater, MN, discuss pilocarpine concentration, tolerability, and patient selection.

There has been a clinical shift toward presbyopia drops as a more common pharmacological means to correct near vision in patients aged 40 to 50. While several FDA-approved drops operate on similar mechanisms, they differ in formulation and concentration, raising questions about their efficacy and safety profiles.

Pilocarpine concentration and mechanism of action

These drops primarily function by inducing miosis, effectively enhancing depth of focus through a pinhole effect. A critical inquiry emerges: What is the optimal concentration that sufficiently enhances near vision while minimizing side effects?

Insights from related medications such as atropine, phenylephrine, and cyclopentolate suggest that varying concentrations can yield different clinical outcomes.

Tolerability and side effects

Dr. Lang emphasizes that excessive amounts of anything can harm patients, and with miotics, this can lead to increased side effects.

High concentrations of pilocarpine can lead to adverse events such as:

  • Dimming of vision
  • Headaches or "brow ache"
  • Myopic shifts
  • Redness, stinging, or burning upon installation
  • Excessive ciliary muscle contraction

Furthermore, excessive miosis may induce negative optical effects, such as diffraction or restricted light entry, which can detract from the patient's visual experience.

Patient selection and compliance for presbyopia drops

Dr. Schaeffer likens the role of lower concentration drops for patients under 50 with some accommodative ability to that of a gym spotter—providing just enough assistance to accomplish a visual task effectively.

When selecting candidates for pilocarpine treatment, several factors must be assessed, including lifestyle, motivation, and any history of refractive surgery. Tailoring the choice of drops to fit a patient's unique lifestyle and sensitivity to side effects is crucial. Since these drops are viewed as optional "lifestyle" medications, patients are generally less tolerant of adverse effects compared to those associated with sight-saving treatments like glaucoma medications.

Interestingly, patients who have undergone refractive surgery, such as LASIK, often demonstrate heightened motivation to use these drops. However, caution is advised if their pre-surgery refractive error or axial length is unknown.

Best practices for prescribing presbyopia drops

Dr. Lang emphasizes that presbyopia drops should be considered a viable alternative alongside traditional solutions like glasses and contact lenses. Practitioners should seize the opportunity to offer pharmaceutical refractive correction.

Managing patient expectations through thorough education during consultations is vital for fostering long-term adherence to treatment. Informing patients that side effects may occur, but often improve within the initial weeks, can enhance compliance and satisfaction.

Conclusion

As the landscape of vision correction evolves, pilocarpine drops present an exciting option for addressing presbyopia. By understanding the relationships among concentration, tolerability, and patient selection, eyecare providers can optimize treatment outcomes and improve their patients' quality of life.

References

  1. Grzybowski A, Kapitanovaite L, Zemaitiene R. An updated systematic review of pharmacological treatments for presbyopia. Adv Ophthalmol Pract Res. 2024;4(4):220-225. Published 2024 Sep 3. doi:10.1016/j.aopr.2024.09.001
  2. Kinney M, Johnson AD, Reddix M, McCann MB. Temporal Effects of 2% Pilocarpine Ophthalmic Solution on Human Pupil Size and Accommodation. Mil Med. 2020;185(Suppl 1):435-442. doi:10.1093/milmed/usz235
  3. Onyszkiewicz M, Hilmers J, Rejdak R, Zrenner E, Straßer T. Effects of Miosis on the Visual Acuity Space under Varying Conditions of Contrast and Ambient Luminance in Presbyopia. J Clin Med. 2024;13(5):1209. Published 2024 Feb 21. doi:10.3390/jcm13051209